Scholarworks Repository

A clinical phase II study of a non-anthracycline sequential combination of cisplatin-vinorelbine followed by docetaxel as first-line treatment in metastatic breast cancer

Show simple item record

dc.contributor.author Shamseddine A.I.
dc.contributor.author Otrock Z.K.
dc.contributor.author Khalifeh M.J.
dc.contributor.author Yassine H.R.
dc.contributor.author Charafeddine M.
dc.contributor.author Abdel-Khalek Z.
dc.contributor.author Chehal A.
dc.contributor.author Bitar N.
dc.contributor.author Jalloul R.
dc.contributor.author Dheiny M.
dc.contributor.author Dandashi A.
dc.contributor.author Wehbeh M.
dc.contributor.author El-Saghir N.S.
dc.contributor.editor
dc.date Jan-2006
dc.date.accessioned 2017-10-05T16:08:02Z
dc.date.available 2017-10-05T16:08:02Z
dc.date.issued 2006
dc.identifier 10.1159/000097945
dc.identifier.isbn
dc.identifier.issn 00302414
dc.identifier.uri http://hdl.handle.net/10938/20148
dc.description.abstract Background: We tested a sequential combination regimen using cisplatin and vinorelbine (PVn) followed by docetaxel as first-line chemotherapy in a phase II clinical trial in metastatic breast cancer (MBC). Patients and Methods: Thirty-five patients were enrolled. Cisplatin 80 mg-m2 was given on day 1 and vinorelbine 30 mg-m2 on days 1 and 8 every 3 weeks for 4 cycles. Responding patients received docetaxel 75 mg-m2 every 21 days for a maximum of 4 cycles. Three patients were excluded from analysis because of death unrelated to treatment. Results: After a median follow-up of 14 months, 32 patients completed the study. The overall response rate was 53.1percent. Complete remission was seen in 5 patients (15.6percent), partial response in 12 (37.5percent), stable disease in 6 (18.75percent), and progressive disease in 9 patients (28.1percent). Median time to disease progression was 8 months (range 1-24). At 24 months, 12 (37.5percent) patients were alive. A total of 183 cycles were administered. Febrile neutropenia was observed in 4 patients (2.2percent). Grade II nephrotoxicity occurred in 12 cycles (6.5percent) and grade III vomiting in 31-183 cycles (16.9percent). Discussion: PVn is a feasible non-anthracycline option as first-line chemotherapy in patients with metastatic breast cancer and has acceptable toxicity. The sequential addition of 4 cycles of docetaxel following 4 cycles of PVn did not improve the overall response rate and results. Copyright © 2006 S. Karger AG.
dc.format.extent
dc.format.extent Pages: (330-338)
dc.language English
dc.publisher BASEL
dc.relation.ispartof Publication Name: Oncology; Publication Year: 2006; Volume: 70; no. 5; Pages: (330-338);
dc.relation.ispartofseries
dc.relation.uri
dc.source Scopus
dc.subject.other
dc.title A clinical phase II study of a non-anthracycline sequential combination of cisplatin-vinorelbine followed by docetaxel as first-line treatment in metastatic breast cancer
dc.type Article
dc.contributor.affiliation Shamseddine, A.I., American University of Beirut Medical Center, Beirut, Lebanon, Division of Hematology-Oncology, Department of Internal Medicine, American University of Beirut-Medical Center, PO Box 113-6044, Beirut 1107 2802, Lebanon
dc.contributor.affiliation Otrock, Z.K., American University of Beirut Medical Center, Beirut, Lebanon
dc.contributor.affiliation Khalifeh, M.J., American University of Beirut Medical Center, Beirut, Lebanon
dc.contributor.affiliation Yassine, H.R., American University of Beirut Medical Center, Beirut, Lebanon
dc.contributor.affiliation Charafeddine, M., American University of Beirut Medical Center, Beirut, Lebanon
dc.contributor.affiliation Abdel-Khalek, Z., American University of Beirut Medical Center, Beirut, Lebanon
dc.contributor.affiliation Chehal, A., American University of Beirut Medical Center, Beirut, Lebanon
dc.contributor.affiliation Bitar, N., Sahel General Hospital, Beirut, Lebanon
dc.contributor.affiliation Jalloul, R., Makassed General Hospital, Beirut, Lebanon
dc.contributor.affiliation Dheiny, M., Hammoud Hospital, Saida, Lebanon
dc.contributor.affiliation Dandashi, A., Islamic Hospital, Tripoli, Lebanon
dc.contributor.affiliation Wehbeh, M., Hammoud Hospital, Saida, Lebanon
dc.contributor.affiliation El-Saghir, N.S., American University of Beirut Medical Center, Beirut, Lebanon
dc.contributor.authorAddress Shamseddine, A.I.; Division of Hematology-Oncology, Department of Internal Medicine, American University of Beirut-Medical Center, PO Box 113-6044, Beirut 1107 2802, Lebanon; email: as04@aub.edu.lb
dc.contributor.authorCorporate University: American University of Beirut Medical Center; Faculty: Faculty of Medicine; Department: Surgery;
dc.contributor.authorDepartment Surgery
dc.contributor.authorDivision
dc.contributor.authorEmail as04@aub.edu.lb
dc.contributor.authorFaculty Faculty of Medicine
dc.contributor.authorInitials Shamseddine, AI
dc.contributor.authorInitials Otrock, ZK
dc.contributor.authorInitials Khalifeh, MJ
dc.contributor.authorInitials Yassine, HR
dc.contributor.authorInitials Charafeddine, M
dc.contributor.authorInitials Abdel-Khalek, Z
dc.contributor.authorInitials Chehal, A
dc.contributor.authorInitials Bitar, N
dc.contributor.authorInitials Jalloul, R
dc.contributor.authorInitials Dheiny, M
dc.contributor.authorInitials Dandashi, A
dc.contributor.authorInitials Wehbeh, M
dc.contributor.authorInitials El-Saghir, NS
dc.contributor.authorOrcidID
dc.contributor.authorReprintAddress Shamseddine, AI (reprint author), Amer Univ Beirut, Med Ctr, Dept Internal Med, Div Hematol Oncol, POB 113-6044, Beirut 11072802, Lebanon.
dc.contributor.authorResearcherID
dc.contributor.authorUniversity American University of Beirut Medical Center
dc.description.cited Acuna LR, 1999, J CLIN ONCOL, V17, P74; Ahn JH, 2005, BREAST, V14, P304, DOI 10.1016-j.breast.2005.02.006; Antón Antonio, 2003, Clin Breast Cancer, V4, P286, DOI 10.3816-CBC.2003.n.034; BERNARD A, 1998, P AN M AM SOC CLIN, V17, pA128; Biganzoli L, 2004, CURR OPIN OBSTET GYN, V16, P37, DOI 10.1097-01.gco.0000114168.77369.51; BRUNO S, 1995, AM J CLIN ONCOL-CANC, V18, P392, DOI 10.1097-00000421-199510000-00006; Burstein HJ, 2001, J CLIN ONCOL, V19, P2722; Costanza ME, 1999, J CLIN ONCOL, V17, P1397; Danova M, 2001, INT J ONCOL, V19, P733; Demiray M, 2005, CANCER INVEST, V23, P386, DOI 10.1081-CNV-200067133; Ershler WB, 2006, ONCOLOGIST, V11, P325, DOI 10.1634-theoncologist.11-4-325; Esteva FJ, 2001, ONCOLOGIST, V6, P133, DOI 10.1634-theoncologist.6-2-133; Esteva FJ, 2004, ONCOLOGIST, V9, P4, DOI 10.1634-theoncologist.9-suppl_3-4; Fulton B, 1996, DRUGS, V51, P1075, DOI 10.2165-00003495-199651060-00011; FUMOLEAU P, 1993, J CLIN ONCOL, V11, P1245; Fumoleau P, 1997, Oncology (Williston Park), V11, P29; GARCIACONDE J, 1994, ANN ONCOL, V5, P854; HENDERSON IC, 1990, CANCER, V66, P1439, DOI 10.1002-1097-0142(19900915)66:14+1439::AID-CNCR28206614213.0.CO;2-M; HENDERSON IC, 1983, CANCER, V51, P2553, DOI 10.1002-1097-0142(19830615)51:12+2553::AID-CNCR28205113293.0.CO;2-7; JONES SE, 1975, CANCER, V36, P90, DOI 10.1002-1097-0142(197507)36:190::AID-CNCR28203601043.0.CO;2-H; Khayat D, 2001, J CLIN ONCOL, V19, P3367; KOLARIC K, 1983, CANCER CHEMOTH PHARM, V11, P108, DOI 10.1007-BF00254257; Martin Miguel, 2004, Clin Breast Cancer, V5, P353, DOI 10.3816-CBC.2004.n.041; Marty M, 1997, EUR J CANCER, V33, pS26; Mayordomo Jose I, 2004, Clin Breast Cancer, V5, P131, DOI 10.3816-CBC.2004.n.017; Mohran Taha Zaki Mohamad, 2004, J Egypt Natl Canc Inst, V16, P8; Morabito A, 2003, BREAST CANCER RES TR, V78, P29, DOI 10.1023-A:1022197109592; Nabholtz JMA, 2003, BREAST CANCER RES TR, V79, pS3; PARIDAENS R, 2003, ANN ONCOL, V14, P443; Perez EA, 2002, ANN ONCOL, V13, P1225, DOI 10.1093-annonc-mdf222; Perez EA, 2005, ONCOLOGY-BASEL, V69, P117, DOI 10.1159-000087813; Shamseddine A, 2005, AM J CLIN ONCOL-CANC, V28, P393, DOI 10.1097-01.coc.0000145335.39398.ee; Shamseddine AI, 1999, AM J CLIN ONCOL-CANC, V22, P298, DOI 10.1097-00000421-199906000-00018; SLEDGE GW, 1988, J CLIN ONCOL, V6, P1811; Therasse P, 2000, J NATL CANCER I, V92, P205, DOI 10.1093-jnci-92.3.205; WEBER BL, 1995, J CLIN ONCOL, V13, P2722
dc.description.citedCount 2
dc.description.citedTotWOSCount 2
dc.description.citedWOSCount 2
dc.format.extentCount 9
dc.identifier.articleNo
dc.identifier.coden ONCOB
dc.identifier.pubmedID 17164589
dc.identifier.scopusID 33846148365
dc.identifier.url
dc.publisher.address ALLSCHWILERSTRASSE 10, CH-4009 BASEL, SWITZERLAND
dc.relation.ispartofConference
dc.relation.ispartofConferenceCode
dc.relation.ispartofConferenceDate
dc.relation.ispartofConferenceHosting
dc.relation.ispartofConferenceLoc
dc.relation.ispartofConferenceSponsor
dc.relation.ispartofConferenceTitle
dc.relation.ispartofFundingAgency
dc.relation.ispartOfISOAbbr Oncology
dc.relation.ispartOfIssue 5
dc.relation.ispartOfPart
dc.relation.ispartofPubTitle Oncology
dc.relation.ispartofPubTitleAbbr Oncology (Switzerland)
dc.relation.ispartOfSpecialIssue
dc.relation.ispartOfSuppl
dc.relation.ispartOfVolume 70
dc.source.ID WOS:000243065500003
dc.type.publication Journal
dc.subject.otherAuthKeyword Cisplatin
dc.subject.otherAuthKeyword Docetaxel
dc.subject.otherAuthKeyword Metastatic breast cancer
dc.subject.otherAuthKeyword Non-anthracycline combination
dc.subject.otherAuthKeyword Phase II study
dc.subject.otherAuthKeyword Vinorelbine
dc.subject.otherChemCAS cisplatin, 15663-27-1, 26035-31-4, 96081-74-2
dc.subject.otherChemCAS dexamethasone, 50-02-2
dc.subject.otherChemCAS diphenhydramine, 147-24-0, 58-73-1
dc.subject.otherChemCAS docetaxel, 114977-28-5
dc.subject.otherChemCAS metoclopramide, 12707-59-4, 2576-84-3, 364-62-5, 7232-21-5
dc.subject.otherChemCAS navelbine, 71486-22-1
dc.subject.otherChemCAS Cisplatin, 15663-27-1
dc.subject.otherChemCAS docetaxel, 114977-28-5
dc.subject.otherChemCAS Taxoids
dc.subject.otherChemCAS Vinblastine, 865-21-4
dc.subject.otherChemCAS vinorelbine, 71486-22-1
dc.subject.otherIndex anthracycline
dc.subject.otherIndex cisplatin
dc.subject.otherIndex dexamethasone
dc.subject.otherIndex diphenhydramine
dc.subject.otherIndex docetaxel
dc.subject.otherIndex metoclopramide
dc.subject.otherIndex navelbine
dc.subject.otherIndex serotonin antagonist
dc.subject.otherIndex adult
dc.subject.otherIndex aged
dc.subject.otherIndex alopecia
dc.subject.otherIndex anemia
dc.subject.otherIndex article
dc.subject.otherIndex breast cancer
dc.subject.otherIndex breast metastasis
dc.subject.otherIndex cancer combination chemotherapy
dc.subject.otherIndex cancer regression
dc.subject.otherIndex chemotherapy induced emesis
dc.subject.otherIndex clinical article
dc.subject.otherIndex clinical trial
dc.subject.otherIndex disease course
dc.subject.otherIndex disease free survival
dc.subject.otherIndex drug dose regimen
dc.subject.otherIndex drug dose sequence
dc.subject.otherIndex drug efficacy
dc.subject.otherIndex drug safety
dc.subject.otherIndex febrile neutropenia
dc.subject.otherIndex female
dc.subject.otherIndex follow up
dc.subject.otherIndex human
dc.subject.otherIndex multiple cycle treatment
dc.subject.otherIndex nephrotoxicity
dc.subject.otherIndex neurotoxicity
dc.subject.otherIndex neutropenia
dc.subject.otherIndex overall survival
dc.subject.otherIndex phase 2 clinical trial
dc.subject.otherIndex priority journal
dc.subject.otherIndex thrombocytopenia
dc.subject.otherIndex treatment outcome
dc.subject.otherIndex treatment response
dc.subject.otherIndex Adult
dc.subject.otherIndex Aged
dc.subject.otherIndex Antineoplastic Combined Chemotherapy Protocols
dc.subject.otherIndex Breast Neoplasms
dc.subject.otherIndex Cisplatin
dc.subject.otherIndex Disease Progression
dc.subject.otherIndex Disease-Free Survival
dc.subject.otherIndex Drug Administration Schedule
dc.subject.otherIndex Female
dc.subject.otherIndex Fever
dc.subject.otherIndex Follow-Up Studies
dc.subject.otherIndex Humans
dc.subject.otherIndex Kidney
dc.subject.otherIndex Middle Aged
dc.subject.otherIndex Neoplasm Staging
dc.subject.otherIndex Neutropenia
dc.subject.otherIndex Survival Analysis
dc.subject.otherIndex Taxoids
dc.subject.otherIndex Treatment Outcome
dc.subject.otherIndex Vinblastine
dc.subject.otherIndex Vomiting
dc.subject.otherKeywordPlus WEEKLY IV-VINORELBINE
dc.subject.otherKeywordPlus FIRST-LINE
dc.subject.otherKeywordPlus INTRAVENOUS VINORELBINE
dc.subject.otherKeywordPlus 2ND-LINE THERAPY
dc.subject.otherKeywordPlus SINGLE-AGENT
dc.subject.otherKeywordPlus CHEMOTHERAPY
dc.subject.otherKeywordPlus TRIAL
dc.subject.otherKeywordPlus CYCLOPHOSPHAMIDE
dc.subject.otherKeywordPlus GEMCITABINE
dc.subject.otherKeywordPlus PACLITAXEL
dc.subject.otherWOS Oncology


Files in this item

Files Size Format View

There are no files associated with this item.

This item appears in the following Collection(s)

Show simple item record

Search Scholarworks


Browse

My Account